Clinical trial
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver…
NCT00047346 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00047346 |
|---|---|
| Title | Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction |
| Official title | A Dose-Finding, Safety, And Pharmacokinetic Study Of The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor OSI-774 (NSC 718781) In Patients With Unresectable Hepatocellular Carcinoma And Moderate Hepatic Dysfunction |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis |
| Enrollment | 24 |
| Start date | Aug 1, 2002 |
| Primary completion | Dec 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: